Chargari C, Castro-Pena P, Toledano I, Bollet MA, Savignoni A, Cottu P, Laki F, Campana F, Fourquet A, Kirova YM. Concurrent use of aromatase inhibitors and hypofractionated radiation therapy. World J Radiol 2012; 4(7): 318-323
Corresponding Author of This Article
Youlia M Kirova, MD, Department of Radiation Oncology, Institut Curie, 26, rue d’Ulm, 75005 Paris, France. firstname.lastname@example.org
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
1Including five patients with neoadjuvant endocrine therapy. BCS: Breast conservative surgery; LN: Lymph node; LND: Lymph node dissection; RT: Radiation therapy.
Table 3 Skin toxicity
Acute toxicity is scored according to the Common Toxicity Criteria for Adverse Events v3; long-term toxicity is scored according to the Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic scale.
Table 4 Reasons for discontinuating aromatase inhibitors therapy prior to 5 yr adjuvant therapy
Reasons for discontinuation
Citation: Chargari C, Castro-Pena P, Toledano I, Bollet MA, Savignoni A, Cottu P, Laki F, Campana F, Fourquet A, Kirova YM. Concurrent use of aromatase inhibitors and hypofractionated radiation therapy. World J Radiol 2012; 4(7): 318-323